10-Q and Current Reports on Form 8-K. All forward-looking statements made in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. Except as required by law, Anebulo undertakes no obligation to update or revise forward-looking statements to reflect new information, future events, changed conditions or otherwise after the date of this press release.
Condensed Balance Sheets
December 31, June 30,
2024 2024
-------------- ----------
Cash and cash equivalents $ 14,998,467 $3,094,200
Total assets 15,841,220 4,073,114
Total liabilities 878,799 260,583
Total stockholders' equity 14,962,421 3,812,531
Condensed Statements of Operations
Three months ended December 31,
-----------------------------------
2024 2023
------------------ --------------
Research and development $ 1,220,535 $ 1,062,672
General and administrative 1,367,616 1,697,787
-------------- -------------
Total operating expenses 2,588,151 2,760,459
-------------- -------------
Loss from operations (2,588,151) (2,760,459)
Other (income) expenses:
Interest expense 59,696 31,838
Interest income (7,067) (75,522)
Grant income (177,703) -
Other (47) 594
-------------- -------------
Total other income, net (125,121) (43,090)
-------------- -------------
Net loss $ (2,463,030) $ (2,717,369)
============== =============
Weighted average common shares
outstanding, basic and
diluted 27,415,430 25,789,739
============== =============
Net loss per share, basic and
diluted $ (0.09) $ (0.11)
============== =============
View source version on businesswire.com: https://www.businesswire.com/news/home/20250214598365/en/
CONTACT: Anebulo Pharmaceuticals, Inc.
Daniel George
Chief Financial Officer
(512) 598-0931
Dan@anebulo.com
(END) Dow Jones Newswires
February 14, 2025 16:05 ET (21:05 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.